Mike Havrilla
Contributor since: 2006
Company: Biorunup.com
Latest Articles
Ventrus Bio Poised For Run-Up Into Second Round Of Phase III Results
Can-Fite BioPharma: Near-Term Clinical Trial And Up-Listing Catalysts
Halozyme: Drug Delivery Specialist With Multiple Near-Term Catalysts
Venaxis: Well-Funded Ahead Of Multiple Catalysts Expected Through Year-End
Halozyme: Drug Delivery Specialist With Multiple Catalysts
Merrimack Poised For Post-Offering Bounce Ahead Of Phase III Results
Ventrus Poised For Run-Up Ahead Of Phase III Results
BioSpecifics Poised For Run Up Into Near-Term FDA Catalyst
Avita Medical: An Under-The-Radar Buy In Regenerative Medicine
Venaxis Poised For Run-Up Into Pivotal Study Results
Titan Pharma: Trading The FDA Run-Up, Round 2
Nymox Pharma: Developing A Potential Long-Term Treatment For BPH
Rockwell Poised For Post-Offering Bounce Ahead Of Phase III Results
Flamel: Near-Term, Under The Radar FDA Catalyst Trade
Delcath Poised For Run-Up Into FDA Advisory Panel Meeting
Durata Therapeutics: Low Floater With Near-Term Phase III Catalyst
AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts
Chembio Diagnostics: Growing Sales And Profits With Near-Term FDA Catalyst
BioLineRx: Israeli Biotech Incubator With Multiple Near-Term Clinical Catalysts
Anika Therapeutics: Growth Stock At Value Prices With Near-Term FDA Catalyst
Anacor Pharma Poised For Rebound Ahead Of Phase III Results
Amicus Therapeutics Poised For Rebound Into December Phase III Results
Lannett Returns To Profitability, Reports Strong Sales Growth
Alexza Poised For Run-Up Into December U.S., EU Approval Decisions
Unilife Poised For Short- And Long-Term Gains
Rigel Pharma: Key RA Drug Data Expected Late 2012 Through H1 2013
Intellipharmaceutics: Drug Delivery Specialist With Potential FDA Approval And Partnership Catalysts
A Near-Term FDA Catalyst For Cornerstone Therapeutics With Hospital-Focused Strategy
Ironwood Pharma: FDA Decision Expected Within Weeks For GI Drug
Sunesis Poised For Run-Up Into Phase III Interim Analysis Next Month
Amicus Therapeutics: Rare Disease Drug Developer Expected To Reveal Phase III Results In 3Q12
AcelRx Pharma: Pain Drug Developer With 2H12 Phase 3 Catalysts